Human serum albumin (HSA) is widely used in clinical and cell culture applications. Conventional production of HSA from human blood is limited by the availability of blood donation and the high risk of viral transmission from donors. Here, we report the production of Oryza sativa recombinant HSA (OsrHSA) from transgenic rice seeds. The level of OsrHSA reached 10.58% of the total soluble protein of the rice grain. Large-scale production of OsrHSA generated protein with a purity >99% and a productivity rate of 2.75 g/kg brown rice. Physical and biochemical characterization of OsrHSA revealed it to be equivalent to plasma-derived HSA (pHSA). The efficiency of OsrHSA in promoting cell growth and treating liver cirrhosis in rats was similar to that of pHSA. Furthermore, OsrHSA displays similar in vitro and in vivo immunogenicity as pHSA. Our results suggest that a rice seed bioreactor produces cost-effective recombinant HSA that is safe and can help to satisfy an increasing worldwide demand for human serum albumin.
展开▼
机译：人血清白蛋白（HSA）广泛用于临床和细胞培养应用。献血的可用性和来自供体的病毒传播的高风险限制了人类血液对HSA的常规生产。在这里，我们报告从转基因水稻种子生产水稻重组HSA（OsrHSA）。 OsrHSA的水平达到了稻米总可溶性蛋白的10.58％。 OsrHSA的大规模生产产生的蛋白纯度> 99％，生产率为2.75 g / kg糙米。 OsrHSA的物理和生化特性表明它等同于血浆来源的HSA（pHSA）。 OsrHSA促进大鼠细胞生长和治疗肝硬化的效率与pHSA相似。此外，OsrHSA显示出与pHSA类似的体外和体内免疫原性。我们的结果表明，水稻种子生物反应器可以生产经济高效的重组HSA，该重组HSA安全并且可以满足全球对人血清白蛋白需求的增长。
展开▼
